Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2014

View Archived Issues

Bayer HealthCare and University of Oxford collaborate on endometriosis and uterine fibroid research

MRC Technology and AstraZeneca renew collaboration to identify novel targets

Medicure acquires minority position in Apicore

Researchers present a novel insulin analogue with improved glycemic control

Japanese approval for Dovobet to treat psoriasis vulgaris

MRZ-9547 assessed in Parkinson's disease models, enters phase I in healthy subjects

Zalviso MAA submitted in Europe

Early clinical results presented for PEX-168

Lundbeck patents novel nAChR alpha7 PAMs

Merck KGaA prepares new BTK inhibitors

Novartis synthesizes novel pyridone derivatives for tuberculosis

New CDK8/CCNC inhibitors synthesized by Roche

Researchers at Roche and Genentech divulge novel RORC modulators for arthritis

Nexavar approved in Canada for differentiated thyroid cancer

Promising phase I data presented for a number of oncolytic immunotherapy candidates

Japan approves first all-oral interferon- and ribavirin-free HCV treatment

Endo and BioDelivery Sciences report data from phase III BEMA buprenorphine trial

Data safety monitoring recommends continuation of phase IIb brilacidin trial

BeiGene initiates phase I trial of PARP inhibitor BGB-290

Cardio3 BioSciences enrolls 120th patient in the phase III CHART-1 study

Celladon provides update on Mydicar development

Mekinist approved in E.U. for metastatic melanoma with a BRAF V600 mutation

Anoro Ellipta approved in Japan for COPD

FDA approves NovoSeven RT for Glanzmann's thrombasthenia

FDA breakthrough therapy designation granted to cell therapy for leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.